close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade
Kodu・Aktsiate loetelu・Oxford Biomedica PLC
Search

Oxford Biomedica PLC

Suletud

606 -1.14

Tugev "osta" hinnang

Hinna uuendus 14. nov 2025, 16:27 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

592

Max

606

Põhinäitajad

By Trading Economics

Sissetulek

-16M

-26M

Müük

-4.8M

73M

Aktsiakasum

-0.11

Kasumimarginaal

-36

Töötajad

900

EBITDA

-11M

-6.1M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+17.32% upside

Turustatistika

By TradingEconomics

Turukapital

106M

777M

Eelmine avamishind

607.14

Eelmine sulgemishind

606

Oxford Biomedica PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. nov 2025, 17:45 UTC

Tulu
Suurimad hinnamuutused turgudel

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

DJ

Loe

14. nov 2025, 17:31 UTC

Tulu
Suurimad hinnamuutused turgudel

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

DJ

Loe

14. nov 2025, 16:15 UTC

Suurimad hinnamuutused turgudel

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

DJ

Loe

14. nov 2025, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

DJ

Loe

14. nov 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

DJ

Loe

14. nov 2025, 22:35 UTC

Tulu
Omandamised, ülevõtmised, äriostud

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

DJ

Loe

14. nov 2025, 22:32 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

DJ

Loe

14. nov 2025, 22:29 UTC

Tulu

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

DJ

Loe

14. nov 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

DJ

Loe

14. nov 2025, 21:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

14. nov 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

DJ

Loe

14. nov 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

DJ

Loe

14. nov 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

DJ

Loe

14. nov 2025, 20:17 UTC

Omandamised, ülevõtmised, äriostud

Several State Attorneys General Oppose Railroad Merger -- WSJ

DJ

Loe

14. nov 2025, 19:29 UTC

Market Talk
Tulu

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

DJ

Loe

14. nov 2025, 18:44 UTC

Market Talk
Tulu

Disney's Growth Now Hinges More on ESPN -- Market Talk

DJ

Loe

14. nov 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

14. nov 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

DJ

Loe

14. nov 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

DJ

Loe

14. nov 2025, 17:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

DJ

Loe

14. nov 2025, 17:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

DJ

Loe

14. nov 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Loe

14. nov 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

DJ

Loe

14. nov 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

DJ

Loe

14. nov 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

DJ

Loe

14. nov 2025, 16:30 UTC

Omandamised, ülevõtmised, äriostud

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

DJ

Loe

14. nov 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

DJ

Loe

14. nov 2025, 15:59 UTC

Market Talk

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

DJ

Loe

14. nov 2025, 15:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

14. nov 2025, 15:06 UTC

Market Talk

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

DJ

Loe

Oxford Biomedica PLC Prognoos

Hinnasiht

By TipRanks

17.32% tõus

12 kuu keskmine prognoos

Keskmine 707.447 GBX  17.32%

Kõrge 969.188 GBX

Madal 450.622 GBX

Põhineb 4 Wall Streeti analüütiku instrumendi Oxford Biomedica PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

4

Osta

0

Hoia

0

Müü

Põhineb 4 analüütiku instrumendi Oxford Biomedica PLC aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
help-icon Live chat